July 31, 2024 12:54 PM EDT

FDA questions Zevra’s resubmitted data for rare disease drug ahead of adcomm

Lei Lei Wu

News Reporter

Ahead of an advisory meeting Friday, the FDA raised questions about the strength of human, mouse and cell data Zevra Therapeutics generated for its treatment …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA questions Zevra’s resubmitted data for rare disease drug ahead of adcomm

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

WuXi AppTec will sell cell and gene therapy business to private equity firm

CMS explains what went into its first round of drug price negotiations

FDA ques­tions Zevra’s re­sub­mit­ted da­ta for rare dis­ease drug ahead of ad­comm

Lei Lei Wu

News Reporter

Sign up to read this article for free.

more like this

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA questions Zevra’s resubmitted data for rare disease drug ahead of adcomm

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

WuXi AppTec will sell cell and gene therapy business to private equity firm

CMS explains what went into its first round of drug price negotiations